CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
LY900014 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04585776
NCT04585776Phase 2Completed
CompareCT.gov

An Exploratory Study Assessing Time in Target Glucose Range Using a New Titration Scheme of LY900014 and Insulin Degludec in Patients With Type 1 Diabetes

Eli Lilly and Company·interventional·Posted Oct 14, 2020·Updated Jun 3, 2022

In Brief

A Phase 2 clinical trial evaluating LY900014 and Insulin Degludec for Type 1 Diabetes. Completed, enrolled 31 participants across 3 sites.

Detailed Summary

In this study, participants with type 1 diabetes (T1D) will take the study drug LY900014 and insulin degludec. The reason for this study is to evaluate the amount of time with glucose values within target range.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedOct 14, 2020
Enrollment StartOct 30, 2020
Primary CompletionMay 27, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.7 years ago

Interventions

LY900014drug

Administered SC

Insulin Degludecdrug

Administered SC